Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B.

Aliment Pharmacol Ther · 2021 · PMC9292801 · PMID 34587302

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although this benefit did not reach statistical significance in HBeAg‐negative population, it should be a consequence in future follow‐up as a significantly further decrease in ALT levels from baseline was observed in patients receiving TMF than those receiving TDF.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.